title: [Chemoradiation treatment of the superior vena cava compression syndrome in small-cell lung cancer].
abstract: The superior vena cava compression syndrome (SVCCS) was detected in 340 patients with small cell lung carcinoma (SCLC): in 44--during establishing primary diagnosis (the primary syndrome), in 10--after courses of chemo- or radiotherapy (the secondary syndrome). In 32 patients with the primary SVCCS therapy was started with chemotherapy courses, a complete clinical effect was noted in 20 (62.5%) of them, on an average, in 11.7 days. Radiotherapy or chemo- and radiotherapy were given to 32 patients: to 12 patients as kind of primary therapy, to 12 patients after a partial effect of chemotherapy, and to 8 patients with the secondary SVCCS. A complete clinical effect was noted in 28 (87.5%) patients, on an average, in 23 days. Complete and partial tumor regressions (an objective effect) were noted in 30% of the patients after chemotherapy and in 75%--after radiotherapy or chemo- and radiotherapy. Marked responses to therapy were noted in single administration of chemotherapeutic drugs at large doses (leukopenia below 2000 cells/microliter, vomiting) or in irradiation of the thoracic cavity at single doses of 3-6 Gy (esophagitis). The authors recommended to plan chemo- and radiotherapy at mean doses in patients with the primary SVCCS, in a localized process or distant metastases, not threatening the patient's life. In the secondary SVCCS developing after chemotherapy, a method of choice is radiotherapy using single doses of 4-6 Gy, 5-8 fractions.
authors.forename: Z P
authors.initials: ZP
authors.lastname: Mikhina
authors.forename: M B
authors.initials: MB
authors.lastname: Bychkov
authors.forename: N B
authors.initials: NB
authors.lastname: Trofimova
authors.forename: K
authors.initials: K
authors.lastname: Gertner
authors.forename: L I
authors.initials: LI
authors.lastname: Motorina
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy*; D008207:Lymphatic Metastasis; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008770:Methylnitrosourea / Q000008:administration & dosage; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012074:Remission Induction; D013479:Superior Vena Cava Syndrome / Q000188:drug therapy / Q000209:etiology / Q000532:radiotherapy*; D013997:Time Factors
chemical_list: D008770:Methylnitrosourea; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate
vernacular_title: Khimioluchevoe lechenie sindroma sdavleniia verkhneĭ poloĭ veny pri melkokletochnom rake legkogo.